Advertisement
Advertisement
U.S. markets open in 4 hours 51 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Northwest Biotherapeutics, Inc. (NWBO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.7650+0.0397 (+5.47%)
At close: 03:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.7253
Open0.7256
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.6725 - 0.7977
52 Week Range0.3900 - 2.0500
Volume3,077,752
Avg. Volume4,610,153
Market Cap752.949M
Beta (5Y Monthly)0.08
PE Ratio (TTM)N/A
EPS (TTM)-0.0630
Earnings DateMay 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for NWBO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • NORTHWEST BIOTHERAPEUTICS INC
    Technical Assessment: Bearish in the Intermediate-TermMarket sentiment remains in the tank and the stock market simply cannot put together a decent rally. The National Association of Active Investment Managers (NAAIM) exposure index has fallen back to 20%, an extremely low equity exposure and a very bearish stance toward equities. This is the second time the index has dropped to 20% in the past six weeks. The seven-week average of exposure has fallen to 30%, the lowest since the pandemic low, as well as in 2015, 2011, and 2008/2009.
    Rating
    Fair Value
    Economic Moat
    7 days agoArgus Research
View more
Advertisement
Advertisement